The turn of the millennium coincided with the branding of a fundamentally different class of enzyme -proteases that reside immersed inside the membrane. This new field was the convergence of completely separate lines of research focused on cholesterol homeostasis, Alzheimer's disease, and developmental genetics. None intended their ultimate path, but soon became a richly-integrated fabric for an entirely new field: regulated intramembrane proteolysis. Our aim in this Special Issue is to focus on the ancient and nearly ubiquitous enzymes that catalyze this unexpected yet important reaction. The pace of progress has been dramatic, resulting in a rapidly-expanding universe of known cellular functions, and a paradigm shift in the biochemical understanding of these once heretical enzymes. More recently, the first therapeutic successes have been attained by targeting an intramembrane protease. We consider these advances and identify oncoming opportunities in four parts: growing spectra of cellular roles, insights into biochemical mechanisms, therapeutic strategies, and newly-emerging topics. Recent studies also expose challenges for the future, including non-linear relationships between substrate identification and physiological functions, and the need for potent and specific, not broad-class, inhibitors.
1. Introduction
Unexpected beginnings
Intramembrane proteases were discovered through studies that had vastly different starting points, ranging from Alzheimer's disease etiology [1] , to cholesterol biosynthesis [2] , and embryogenesis [3] . The only common guiding principle was the appreciation that protein domains can be shed from the membrane as a regulatory mechanism, and in some cases these events were central to diseases. The goal was to understand the molecular players and reaction mechanisms underlying biology and disease [4] .
One instructive example is the amyloid-β precursor protein (APP), a large, single-pass membrane protein from which an internal 42-residue peptide was found in the senile plaques of Alzheimer's patients [11, 19, 18] . The C-terminus of Aβ42 resided within the APP transmembrane segment, but it was assumed that proteolysis followed membrane breach. It was only cloning of the early-onset Alzheimer's disease gene presenilin, and subsequent biochemical detective-work with its 9 transmembrane integral membrane protein product, that began to raise the possibility of this proteolysis occurring naturally within the membrane by a novel aspartyl protease [1] . Two years earlier the site-2 protease (S2P) intramembrane metalloenzyme was cloned as the activity that liberates cholesterol-activating transcription factors by cleaving transmembrane segments [2] . Then, 2 years later, the key developmental signaling factor rhomboid was identified to be an intramembrane serine protease [3] . Today these three superfamilies of intramembrane proteases are known to catalyze these unusual reactions ( Fig. 1) , although others may still await discovery.
What could not have been predicted was the widespread nature of the enzymes that were uncovered by these focused studies, and the broad biology that they govern. Intramembrane proteases are present from archaea to plants and animals, and are among the most widely-distributed membrane proteins in all life forms [5] [6] [7] .
Since these seminal beginnings, the pace of progress has been rapid in three areas: defining cellular roles, elucidating biochemical mechanisms, and designing therapeutic strategies. Research on each of the three enzyme families lies at different points along this pathway, and experience both common and unique challenges. This Special Issue collates the current progress and explores future opportunities of this burgeoning field of biochemistry.
Part I: Cellular functions
The first intramembrane protease to be discovered was site-2 protease, a metalloenzyme that regulates cholesterol/fatty acid synthesis and stress responses [2] . Fittingly Rawson begins our Special Issue by describing the historic discovery of this central enzyme, which, as a rule, plays essential functions in metazoans [9] . However, Rawson also details recent exceptions to this rule, highlighting discovery of X-linked hypomorphic mutations in S2P that lead to human congenital skin and neurological pathologies, and an unexpected caspase-dependent cleavage mechanism that renders flies null for S2P entirely viable. S2P also plays prominent roles in bacteria, where they control versatile circuits that trigger a wide spectrum of pathways, ranging from stress responses to virulence gene expression [10] . In most, but not all, cases the cleavage ultimately frees a transcription factor domain to activate target gene expression. Schneider and Glickman discuss this classical yet broad function, adding two new categories for the currently-known functions of S2Ps in various bacteria.
One of the most pursued, yet evasive, enzyme targets has been γ-secretase (the presenilin holoenzyme complex). The reason for this discrepancy is the multifaceted biology underlying its function [11] . By integrating studies from human genetics and mouse models, Jurisch-Yaksi et al. provide a comprehensive overview of the expanding biological roles that γ-secretase plays in vertebrate animals. This functional spectrum illustrates both the challenges, and opportunities, in therapeutic intervention against γ-secretase.
Long considered to be "orphan cousins" of γ-secretase, Fluhrer and colleagues describe how signal peptide peptidases (SPPs) are rapidly emerging as key regulators of various specific functions in eukaryotes, particularly in the vertebrate immune system [12] . SPP-like (SPPL) proteases reside in a variety of organelles, albeit not in the nucleus or mitochondria/plastids (perhaps because bacteria lack aspartyl intramembrane proteases). SPP was discovered as the activity that cuts signal peptides [7] , but some of the resulting fragments have post-targeting functions in immune surveillance. SPPL2a/b, in contrast, are present only in vertebrates where they reside outside the ER and cleave signaling molecules that organize immune system function. Studies in small model organisms also hint at developmental functions for SPP during embryogenesis, although specific functions remain to be worked out.
Rhomboid proteases were the last superfamily to be discovered as intramembrane proteases [3] . Although central to cell signaling in Drosophila development, the functions of rhomboid proteins in mammals, which served as the subjects for discovery of the other two intramembrane protease families, has remained mysterious [13] . Bergbold and Lemberg now review new discoveries that are starting to shed light on rhomboid function in mammals. Particularly intriguing is the discovery of inactive rhomboid proteins that lack protease activity but regulate the trafficking and quality control of other membrane proteins. Unexpected links to diseases are also starting to emerge, although it is too early to know the extent to which rhomboid proteins are involved.
In contrast to the progress with vertebrate rhomboid proteins, the function of rhomboid proteases in bacteria remain limited [14] , even despite increasingly deep understanding of their biochemical mechanisms and structures. Rather considers the current state of progress with prokaryotic organisms, and highlights new approaches based on more sophisticated bioinformatic co-segregation analysis, which tracks the genomic co-occurrence of rhomboid proteins with other membrane proteins throughout evolution, as a new means to identify important substrates. Although promising, these targets are yet to be validated.
A central theme to emerge from studying all eukaryotic intramembrane proteases is the importance of subcellular trafficking to regulating proteolysis [15] . Morohashi and Tomita explore how subcellular traffic determines the ultimate outcome of these key proteolytic events, from whether and when the protease and substrate meet, to the different outcomes that depend on where the cleavage takes place in a cell.
Clearly studies over the past few years have emphasized how frequently intramembrane proteases are being found at the nexus of key biological processes. Given the fact that the majority of intramembrane proteases functions remain a mystery, the field is poised for many new and exciting discoveries.
Part II: Biochemical mechanisms
Although even early data implied that hydrolysis of peptide bonds was being catalyzed within the cell membrane by unusual, integral membrane enzymes, the uncomfortable conceptual problem was the belief that the membrane, being a water-excluding environment, should be unable to support hydrolysis [1] [2] [3] .
What had been missing for all three enzyme candidates is the biochemical standard of proof that the isolated polypeptides, in pure form in vitro, could catalyze the hydrolysis of peptide bonds. Over the past decade this challenge has been overcome, and pure enzyme systems are now routine for all three families of intramembrane proteases, albeit not necessarily for every individual member of interest.
Yet even with these powerful tools in hand, deciphering the enzymatic mechanism in detail can only be realized with a solid structural foundation. Although this is the common bottleneck with membrane proteins, intensive efforts were rewarded unexpectedly early (Fig. 1) .
Brooks and Lemieux discuss the first high-resolution structures to be solved of bacterial rhomboid proteases [16] . Subsequent work has started to integrate enzymatic analysis, application of biophysical methods, and further structures solved under various conditions. Although a more detailed model of intramembrane proteolysis is starting to emerge, many key gaps nevertheless remain and are highlighted.
Kroos and Akiyama continue this theme with S2Ps, which pose a greater challenge to structural analysis; to date the structure of only one S2P ortholog has been solved [17] . Since S2Ps cleave only substrates that have had their ectodomain removed by site-1 cleavage, cytoplasm Fig. 1 . The three known families of intramembrane proteases. X-ray crystal structure models for each intramembrane protease family prototype are diagrammed in a membrane bilayer. The intramembrane catalytic residues are shown in yellow stick format emanating from transmembrane cylinders, while the catalytic zinc is depicted in green. The prokaryotic enzymes are Escherichia coli rhomboid GlpG (PDB ID: 2NRF); Methanocaldococcus jannaschii site-2 protease MJ0392 (PDB ID: 3B4R), and the Methanoculleus marisnigri presenilin JR1 (PDB ID: 4HYD). These bacterial and archaeal enzymes are serving as structural prototypes for understanding intramembrane protease mechanisms.
isolated S2P extracellular domains that may serve gating functions have also been studied structurally. Kroos and Akiyama translate the wealth of molecular genetic and biochemical data with available structural models, yielding new predictions that could drive future exploration into S2P mechanism. A major landmark has been achieved in the past few months (see Ref. [18] ); the first structure of a true presenilin-family protease has been solved to high resolution (Fig. 1) . Wolfe describes how the archaeal presenilin prototype serves as a critical first blueprint for decoding the mechanism of these important but enigmatic enzymes. Yet even before a structural framework became available, the progress on presenilin mechanism using detailed biochemical interrogation has been impressive, yielding new and unexpected enzymatic insights including two separate but processive pathways for generating a wide spectrum of products.
Collectively these structural achievements have unveiled the first molecular snapshots of all three intramembrane protease families, and proof that their catalytic residues are indeed immersed within the plane of the membrane, as predicted ( Fig. 1 in yellow) . They also reveal the active sites to be hydrated and suggest how water might gain entry, but what remains woefully missing is detailed information on substrate-enzyme interactions along the cleavage reaction.
Part III: Therapeutic strategies
The maturity of a field is often measured by its ability to convert the depth of accumulated knowledge to the benefit of mankind. While it is clear that research on many intramembrane proteases is rapidly moving in this direction, achieving this ultimate goal requires a thorough and integrated understanding of both the cellular functions and biochemical mechanisms. Yet even despite their obvious complexity, it is exciting that the first clinical successes have recently been attained for an intramembrane protease, with additional promising strategies already appearing on the horizon.
γ-Secretase was first identified as a protease implicated in Alzheimer's disease and immediately became a target for designing protease inhibitors [19] . However, inhibition led to severe toxicity due to blocking the processing of other substrates, especially the Notch receptor. As described by Golde and colleagues, further investment in biochemical research resulted in the identification of drugs that allowed processing but shifted the cleavage site in APP. This simple observation raised hope that not inhibition, but modulation of this essential protease activity could be turned to therapeutic advantage, which is currently undergoing clinical trials. Nevertheless the investment and hard work into γ-secretase is beginning to pay off in an unexpected realm: three anti-γ-secretase drugs have recently entered the clinic as treatments for a variety of cancers including pancreatic cancer. This repurposing underscores the importance of thorough basic research for identifying unintended therapeutic opportunities.
Two further examples set the stage for future therapeutic interventions (with many more examples on the way), although work remains before even the first rigorous tests can be attempted.
Some of the greatest global health and economic challenges today are inflicted by protozoan parasites [20] . The diversity of these organisms is staggering, yet Sibley argues that intramembrane proteases are emerging as possible common targets for multiple diseases. Essential functions have been identified for both rhomboid proteases and SPP in the malaria parasite, as well as rhomboid proteases in other unrelated parasites. These observations raise the exciting possibility of being able to target a diverse array of parasitic diseases with a single enzyme target, although compounds of sufficient potency and specificity have yet to be demonstrated.
Looking deeper into the future, Chen and McQuibban describe the ascent of the mitochondrial rhomboid protease PARL into one of the most studied -and promising -avenues into the therapeutic realm [21] . Several independent lines of study in type 2 diabetes and Parkinson's disease have converged on PARL. In fact, recently even mutations in PARL itself have been found in patients with both illnesses, although it is not yet clear whether the mutations play a role in disease.
Chen and McQuibban argue that PARL may be a master regulator of mitochondrial stress responses through interplay of regulating apoptosis, mitophagy and organelle morphology. Since PARL appears to play different functions in healthy versus damaged mitochondria, therapeutic opportunities may exist. The challenge lies in deciphering the complex regulatory network surrounding PARL that involves phosphorylation/ dephosphorylation, proteolysis, mitochondrial-nuclear signaling, and at least three distinct substrates. Although these are early times for PARL research, as argued by Chen and McQuibban the therapeutic promise of this complex "gate-keeper" enzyme should not be under-estimated.
Part IV: Emerging topics
We conclude our Special Issue by considering a few emerging topics: two areas of biology where the prominence of RIP has been slower to emerge are virology and plant biology. Ye provides a collection of new roles that S2Ps and SPPs play in virus infection on the one hand, and the antiviral host response on the other [22] . Only rhomboid proteases seem devoid of functions in these virus combat zones, although absence of evidence should not be taken as evidence of absence.
In contrast, the genomes that encode by far the greatest number of intramembrane proteases are those of plants, yet only recently have concerted efforts yielded the first insights [23] . In fact, perhaps the clearest progress has been in chloroplasts, which contain both S2P and rhomboid proteases (in contrast to mitochondria, which apparently lost S2P). Adam argues that chloroplasts act as a nexus in which organelle morphogenesis, chloroplast-nuclear communication, and developmental signaling are intricately controlled by S2P and rhomboid intramembrane proteases. Further research with plants is likely to provide enormously fertile ground, since 10% of plant transcription factors are membrane-anchored and plants encode a vast arsenal of intramembrane proteases.
Finally, Kinch and Grishin take us back to the beginning by reconsidering rhomboid protease evolution [24] . Intramembrane proteases are nearly ubiquitous enzymes across all life forms, presenting a wealth of biological settings for analysis, yet complicating evolutionary interpretations. Kinch and Grishin use network-based clustering to present a provocative view of rhomboid protease evolution, which thus far has been studied the most extensively of any intramembrane protease. They suggest that the last universal common ancestor already had developed two rhomboid proteasesthe second being PARL-like. Applying similar clustering analyses to other intramembrane proteases could help determine which themes might be common, versus different, in intramembrane protease evolution.
What lies ahead?
Clearly tremendous strides have already been made in understanding intramembrane proteases, and the pace of progress is accelerating. So much so, in fact, that a dedicated Gordon Research Conference has recently been established to maintain dialogue among an increasingly multidisciplinary and international field ("Regulated Proteolysis of Cell Surface Proteins," March 30-April 4, 2014, Venture, CA).
Looking forward, a different area stands out for each intramembrane protease family as exciting opportunities for immediate investment. For rhomboid proteases, a key challenge lies in finding physiologically-relevant substrates that go on to regulate cell function, rather than compiling lists of "bystander" proteins whose cleavage occurs physiologically, but is inconsequential for the cell. In that light, current proteomic and bioinformatics methods are only starting to offer resources for such novel membrane enzymes [8] . Despite the advantages of using inhibitors to glean deeper physiological and biochemical insights with potential for therapeutic opportunities, not a single inhibitor has yet been developed for any S2P. In contrast, γ-secretase has been the subject of intense research into both its substrate repertoire and inhibitor development. However, its biochemical mechanism is far more complex than that of rhomboid or S2P. Since the first high-resolution structure of a true presenilin homolog has only recently been attained, the enormous task of interrogating γ-secretase mechanism through this new lens is only now beginning.
Investing effort into these three important, albeit challenging, technical areas is likely to accelerate progress even further, making for a truly exciting journey ahead.
